stockrow
Friday 6 November 2026
Export LUNG’s income statement to Excel — free account
Pulmonx Corporation
LUNG Healthcare Medical Devices
Pulmonx Corporation’s revenue for fiscal 2025 (year ended December 2025) was $90.5 million, up 8.01% from fiscal 2024.
- Revenue
- +6.20%
- EPS
- +42.8%
- Free cash flow
- +61.3%
- Total debt
- +1.57%
Quarter to September 2026, against a year earlier
2.56
0.00
0.00%
Follow LUNG
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
4 | 3 | 3 | 3 |
+8 more TTM periods Free account |
| (90.31%) | (88.87%) | (86.22%) | (77.19%) | ||
| (34.25%) | (36.74%) | (39.31%) | (36.97%) | ||
ROIC |
(129.86%) | (141.03%) | (153.90%) | (158.98%) | |
Return on Tangible Assets |
(65.38%) | (69.12%) | (70.10%) | (64.41%) | |
Average Days of Receivables |
49.40 | 51.12 | 44.64 | 48.69 | |
Free Cash Flow per Share |
(0.59) | (0.72) | (0.70) | (0.81) | |
Free Cash Flow |
(25.61) | (30.67) | (29.41) | (32.83) | |
Capital Expenditures |
(0.03) | (0.11) | (0.16) | (0.45) | |
| Other line items | |||||
Cash ROIC |
(20.51%) | (23.11%) | (20.31%) | (20.38%) | |
Accounts Receivable Turnover |
6.88 | 6.21 | 7.14 | 7.18 | |
Accounts Payable Turnover |
3.67 | 3.57 | 5.60 | 6.04 | |
Inventory Turnover |
1.27 | 1.23 | 1.31 | 1.43 | |
Average Days of Payables |
82.14 | 85.05 | 58.42 | 61.02 | |
Days of Inventory on Hand |
281.02 | 298.18 | 274.29 | 247.60 | |
Tax Rate |
0.01 | 0.01 | 0.01 | 0.01 | |
Research and Development Expense of Revenue |
21.83% | 22.14% | 22.17% | 21.54% | |
Selling, General and Administrative Expense of Revenue |
99.97% | 107.87% | 112.10% | 111.95% | |
Share Based Compensation of Revenue |
17.67% | 19.72% | 22.31% | 23.46% | |
Interest Coverage |
(9.39) | (12.29) | (15.54) | (17.01) | |
Operating CF/Net income |
0.60 | 0.64 | 0.55 | 0.60 | |
Depreciation/Fixed assets |
0.68 | 0.57 | 0.44 | 0.33 | |
Capex/Depreciation |
(0.03) | (0.10) | (0.18) | (0.62) | |
Revenue per Share |
2.06 | 2.06 | 2.11 | 2.22 | |
Operating CF per Share |
(0.59) | (0.72) | (0.70) | (0.80) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.01 |
Columns are period end dates · fundamentals updated 5 Nov 2026